19 registrations that name hCG as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Trial FinderFDA-approvedRead from ClinicalTrials.gov Oct 20, 2026The hCG peptide page
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 19 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 19 registrations
RecruitingNCT07004192
The Role of hCG in Thawed Embryo Transfer
Phase 4
Fertility Center of Las Vegas
About 220 people
Started Jun 2, 2025
In plain words A Phase 4 study of hCG in female participants 18 and older, run by Fertility Center of Las Vegas. It plans to enroll about 220 people at 1 US site.
Female adult expecting to receive transfer of a thawed embryo.
At least one available frozen blastocyst of transferrable quality.
Non-menopausal female with at least one antral follicle.
Use of pre-implantation genetic testing (PGT), embryos derived from donor oocytes and/or donor sperm, a gestational carrier, and history of prior transfer(s) regardless of outcome are allowed.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
HCG injection; No intervention
Registered summary
This prospective randomized trial will assess the relevance, if any, of a corpus luteum induced by hCG in transfers of thawed embryos.
Where, as registered
1 US site in 1 state.
RecruitingNCT04064840
GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
Phase 3
The University of Hong Kong
About 784 people
Started Sep 1, 2019
In plain words A Phase 3 study of hCG in female participants 18 to 42, run by The University of Hong Kong. It plans to enroll about 784 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 42. Conditions: Subfertility.
What it tests, as registered
IVF: Decapeptyl and hCG; FET: Decapeptyl; IVF: hCG and normal saline; FET: Normal Saline
Registered summary
The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.
Where, as registered
No US site; China (1).
RecruitingNCT06150703
Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles
Phase 3
Assistance Publique - Hôpitaux de Paris
About 652 people
Started Jun 27, 2024
In plain words A Phase 3 study of hCG in female participants 18 to 39, run by Assistance Publique - Hôpitaux de Paris. It plans to enroll about 652 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 39. Conditions: In Vitro Fertilization; ICSI Intracytoplasmic Spermatozoid Injection.
Patients requiring conventional IVF or IVF with sperm injection (ICSI) from the partner or donor under the conditions of management defined by French law.
Patients aged 18 to 39 included
First or second attempt at IVF or ICSI for pregnancy
BMI < 35 kg/m2
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Ovulation induction with hCG + Luteal phase support with vaginal progesterone; Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin
Registered summary
The development of stimulation protocols for in vitro fertilisation (IVF) has led to a paradox. It has now been established that obtaining a large number of oocytes is a key to success, but that it is also a risk factor for embryo transfer failure after puncture (disruption of endometrial receptivity due to luteal insufficiency) and a risk factor for complications such as ovarian hyperstimulation syndrome (OHSS).
Where, as registered
No US site; France (1).
RecruitingNCT06896617
Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)
Phase 4
Fundacion Clinic per a la Recerca Biomédica
About 334 people
Started Feb 1, 2025
In plain words A Phase 4 study of hCG in female participants 18 to 41, run by Fundacion Clinic per a la Recerca Biomédica. It plans to enroll about 334 people at 1 site, none in the US.
In pregnancies achieved through programmed frozen embryo transfer cycle (PC-FET) and modified natural frozen embryo transfer (mNC-FET), to determine whether there are differences in endothelial and placental function, maternal cardiovascular function, fetal growth and fetal cardiovascular and cerebral programming and to assess whether there is an association between these differences and the plasma concentrations of the main secretion products of the Corpus Luteum (CL) with vasoactive and angiogenic action.
Where, as registered
No US site; Spain (1).
RecruitingNCT07340827
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Phase 3
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
About 266 people
Started Feb 4, 2026
In plain words A Phase 3 study of hCG in female participants 18 to 42, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. It plans to enroll about 266 people at 21 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 42. Conditions: Infertility.
Participants who are premenopausal wishing to conceive
Participants with maximum 1 previous stimulation for assisted reproductive technology (ART) without pregnancy
Japanese Participants
Participants are women with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency congenital or acquired
4 more inclusion criteria and the exclusion criteria are on the listing.
The purpose of this study is to assess the efficacy and safety of follitropin alfa/lutropin alfa in Japanese participants with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency undergoing Assisted reproductive technology (ART). The study duration is approximately 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy in Part A.
Where, as registered
No US site; Japan (21).
RecruitingNCT06875752
Is There a Need for Luteal Support in Modified Natural Cycle Frozen Embryo Transfer Cycles
Phase 4
Dunamenti REK Istenhegyi IVF Center
About 180 people
Started Apr 12, 2025
In plain words A Phase 4 study of hCG in female participants 18 to 40, run by Dunamenti REK Istenhegyi IVF Center. It plans to enroll about 180 people at 5 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 40; healthy volunteers accepted. Conditions: Luteal Support; Frozen Embryo Transfer (FET).
Age 18-40 years at the time of vitrification
At least one good quality blastocyst frozen
Planned 1 blastocyst transfer
<3 failed previous ETs
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
no luteal support; Vaginal Progesterone; Progesterone plus HCG
Registered summary
Without progesterone there is no pregnancy. Following ovulation, the endocrine function of the follicle changes and progesterone replacing estradiol becomes its main secretory product. In the follicular phase the increasing amount of estradiol secreted by the growing follicle builds up the endometrium, while in the luteal phase progesterone, the main product of the corpus luteum, prepares the endometrium for implantation. This process is called decidualization. If implantation occurs, human chorionic gonadotropin (hCG) secreted by the trophopblasts maintains the function of the corpus luteum. The full summary is on the listing.
Where, as registered
No US site; Hungary (5).
RecruitingNCT05586802
Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
Phase 3
Georgios Papadakis
About 150 people
Started Mar 21, 2023
In plain words A Phase 3 study of hCG in male participants 16 to 65, run by Georgios Papadakis. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 16 to 65. Conditions: Klinefelter Syndrome.
Age range: 16-40 years old
Intention to become parent or interest in fertility preservation
Confirmed azoospermia (lack of spermatozoids) after centrifugation of one semen sample
Age range: 18-65 years old
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Anastrozole; Semaglutide; human chorionic gonadotropin; Testosterone gel
Registered summary
The study seeks primarily to determine whether modulation of systemic and testicular sex steroids balance by aromatase inhibitors will positively affect the metabolic health and spermatogenesis of men with Klinefelter syndrome (KFS) as compared to the current state of the art for each issue. The full summary is on the listing.
Where, as registered
No US site; Switzerland (1).
RecruitingNCT07816562
Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)
Phase 3
Fundación para la Investigación del Hospital Clínico de Valencia
About 126 people
Started Sep 17, 2024
In plain words A Phase 3 study of hCG in female participants 18 to 42, run by Fundación para la Investigación del Hospital Clínico de Valencia. It plans to enroll about 126 people at 1 site, none in the US.
Women with low ovarian response classified within one of the groups defined by the POSEIDON criteria.
The exclusion criteria are on the listing.
What it tests, as registered
Human chorionic gonadotropin (hCG); Follitropin delta; Triptorelin
Registered summary
This study aims to compare different ovulation triggering strategies in women with low ovarian reserve undergoing fresh in vitro fertilization (IVF) cycles. Ovulation triggering is a key step in IVF treatment, as it determines final oocyte maturation prior to oocyte retrieval. Participants are randomly assigned to one of three ovulation trigger approaches: human chorionic gonadotropin (hCG) alone, follitropin delta combined with hCG, or dual trigger using a gonadotropin-releasing hormone (GnRH) agonist plus hCG. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
RecruitingNCT07425990
FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles
No phase
University of Novi Sad
About 120 people
Started Mar 13, 2026
In plain words A study of hCG in female participants 18 to 40, run by University of Novi Sad. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 40. Conditions: Infertility Female; Frozen Embryo Transfer (FET).
Women aged 18 to 40 years
Regular menstrual cycles (26-35 days)
Scheduled for frozen embryo transfer (FET) in a natural menstrual cycle
Normal gynecological ultrasound findings without clinically significant uterine abnormalities
1 more inclusion criterion and the exclusion criteria are on the listing.
The goal of this clinical trial is to learn whether different natural approaches to preparing the uterus for frozen embryo transfer (FET) can improve pregnancy success in women undergoing in vitro fertilization (IVF) treatment. The main questions it aims to answer are: 1. Is a completely natural menstrual cycle more successful than a natural cycle in which ovulation is triggered with medication when preparing for frozen embryo transfer? 2. The full summary is on the listing.
Where, as registered
No US site; Serbia (1).
RecruitingNCT07861399
Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal Responders
No phase
Al-Azhar University
About 100 people
Started Sep 1, 2026
In plain words A study of hCG in female participants 20 to 40, run by Al-Azhar University. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 20 to 40. Conditions: ICSI; IVF; Normal Responders; Infertility Assisted Reproductive Technology; Infertile Women Undergoing IVF or ICSI; Infertile Women Undergoing ART; Triggering Ovulation; Oocyte Maturation.
Women aged 20-40 years.
Body mass index (BMI) between 18 and 30 kg/m².
Undergoing ICSI treatment using a GnRH antagonist protocol.
Normal ovarian reserve and expected normal ovarian response.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Dual trigger (human chorionic gonadotropin plus GnRH-agonist); hCG trigger
Registered summary
To compare the embryological and reproductive outcomes of dual trigger versus conventional hCG trigger for final oocyte maturation in normal responder patients undergoing ICSI cycles.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07108621
hCG Priming in Women With Diminished Ovarian Reserve
Phase 3
Kristine Loessl
About 80 people
Started Jan 25, 2026
In plain words A Phase 3 study of hCG in female participants 18 to 40, run by Kristine Loessl. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 40. Conditions: Infertility, Female; Ovarian Reserve; In Vitro Fertilization (IVF).
The aim of this randomized controlled trial is to further examine the possible effects of low dose human chorionic gonadotropin (hCG) priming for eight weeks in women with diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The investigators want to retest the findings of our first study in an identical paired design (NCT04643925), as an increase of 1.5 in mean number of oocytes retrieved is clinically relevant. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
RecruitingNCT07028710
Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle
No phase
University Hospital, Montpellier
About 40 people
Started Jan 12, 2026
In plain words A study of hCG in female participants of any age, run by University Hospital, Montpellier. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants of any age; healthy volunteers accepted. Conditions: Luteal Phase Insufficiency.
At least 1 follicle of 14 mm or more
Endometrium of 6 mm or more
Plasma luteinizing hormone (LH) less than 2 times basal level (measured at the beginning of the cycle between D1 and D4) and progesteronemia less than 1.5 ng/mL
For whom ovulation induction with recombinant hCG (Ovitrelle) is then proposed (standard care).
The exclusion criteria are on the listing.
What it tests, as registered
hCG
Registered summary
This pilot study evaluates how progesterone levels change after hCG-triggered ovulation in modified natural cycles. Forty women preparing for frozen embryo transfer will have blood tests over 6 days to monitor hormone levels. The goal is to understand whether hCG affects the timing of the luteal phase and embryo implantation.
Where, as registered
No US site; France (1).
RecruitingNCT06904599
Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment
Phase 2
Hospital Universitario Dr. Jose E. Gonzalez
About 20 people
Started Feb 1, 2025
In plain words A Phase 2 study of hCG in people 18 and older, run by Hospital Universitario Dr. Jose E. Gonzalez. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Acute Graft Versus Host Disease.
Aged 18 years or older.
Any gender.
Post-allogeneic transplantation status (haploidentical or identical) of hematopoietic cells.
Presenting recently onset aGVHD, grades 2 to 4, and requiring systemic steroid use as determined by the treating physician.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Human chorionic gonadotropin (hCG); Prednisone; Dexamethasone
Registered summary
Graft-versus-host disease is a complication of allogeneic hematopoietic cell transplantation with high morbidity and mortality. The standard treatment is corticosteroids, and based on the response within 3 to 7 days, a second-line therapy is added, which is expensive and not easily accessible. The administration of human chorionic gonadotropin has shown therapeutic effectiveness in 50% of patients in reported clinical cases.
Where, as registered
No US site; Mexico (1).
Not yet recruitingNCT07557615
hCG Treatment for Rehabilitation From a TBI
Early phase 1
VA Office of Research and Development
About 50 people
Starts Jan 1, 2027 (estimated)
In plain words An early phase 1 study of hCG in male participants 18 to 65, run by VA Office of Research and Development. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 65. Conditions: Traumatic Brain Injury.
Subject is 1-month but < 6-month post-traumatic brain injury (TBI) with a moderate to severe traumatic brain injury (msTBI) defined as Glasgow Coma Scale (GCS) 4-12 (inclusive) at the time of the traumatic brain injury (TBI), and/or at the…
Stable doses of any medication, supplement or medical food that may affect brain function, unless deemed medically necessary by the patient's physician for optimal healthcare
Fluent in English
Reasonable expectation of availability to receive the 24-week course of therapy and be available for follow up evaluations
The exclusion criteria are on the listing.
What it tests, as registered
Ovidrel; Placebo
Registered summary
The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07540611
Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive
No phase
Indira IVF Hospital Pvt Ltd
About 860 people
Starts Jul 17, 2026 (estimated)
In plain words A study of hCG in male participants of any age, run by Indira IVF Hospital Pvt Ltd. It plans to enroll about 860 people at 8 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants of any age; healthy volunteers accepted. Conditions: APHRODITE Group.
What it tests, as registered
No intervention; hCG + FSH therapy
Registered summary
The goal of this clinical trial is to determine whether short-term gonadotropin therapy (hCG + FSH) can increase sperm availability for ICSI in men with idiopathic non-obstructive azoospermia (NOA) and hypogonadism. The main questions it aims to answer are: Does hormonal optimization improve the likelihood of obtaining usable sperm (via ejaculate or micro-TESE) by Week 16? Does hormonal therapy reduce the need for micro-TESE or improve downstream embryological and clinical outcomes? Because there is a comparison group, researchers will compare hCG + FSH hormonal therapy with standard-of-care… The full summary is on the listing.
Where, as registered
No US site; India (8).
Not yet recruitingNCT07633002
The Application of HCG in Luteal Support for Frozen Embryo Transfer in Ovulation Cycle of Obese Women
No phase
The Second Hospital of Shandong University
About 750 people
Starts Jul 1, 2026 (estimated)
In plain words A study of hCG in female participants 22 to 37, run by The Second Hospital of Shandong University. It plans to enroll about 750 people and lists no sites yet.
Age ≤37 years old ② Prepare the endometrium in the natural cycle/ovulation induction cycle ③ BMI≥24 according to the overweight standard for the Asian population ④ Single blastocyst transfer (including IVF and ICSI-assisted pregnancy) ⑤ At…
The exclusion criteria are on the listing.
What it tests, as registered
Human Chorionic Gonadotropin
Registered summary
This study aims to explore whether the application of low-dose HCG in luteal support can improve the pregnancy outcomes of natural cycle frozen embryo transfer in obese patients
Where, as registered
No sites listed yet.
Not yet recruitingNCT07569302
Triggering Ovulation in Normo-responders Using a Modified Dual Trigger Protocol or HCG Trigger
Phase 2
Bedaya Hospital
About 196 people
Starts Jun 1, 2026 (estimated)
In plain words A Phase 2 study of hCG in female participants 18 to 40, run by Bedaya Hospital. It plans to enroll about 196 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 40. Conditions: Infertility (IVF Patients).
GnRH antagonist IVF cycle
Normo-responders to induction of ovulation
The exclusion criteria are on the listing.
What it tests, as registered
Modified dual trigger; HCG
Registered summary
The aim of this randomized controlled study is to compare the efficacy of a modified dual trigger protocol \[a single bolos of HCG combined with two successive doses of a GnRH agonist \] with HCG \[a single bolos administered 36 hours before oocyte retrieval \] in triggering ovulation in normo-responders undergoing ovarian stimulation using the antagonist protocol.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT07569289
Triggering Oocyte Maturation in POSEIDON Group 3 and 4 Poor Responders Using Double Trigger or HCG Trigger
Phase 2
Bedaya Hospital
About 164 people
Starts Jun 1, 2026 (estimated)
In plain words A Phase 2 study of hCG in female participants 18 to 40, run by Bedaya Hospital. It plans to enroll about 164 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 40. Conditions: Infertility.
POSEIDON group 3 and 4
GnRH antagonist IVF cycle
The exclusion criteria are on the listing.
What it tests, as registered
Double trigger; HCG trigger
Registered summary
The aim of this randomized controlled study is to compare the efficacy of double trigger protocol \[ the co-administration of GnRH agonist with HCG ( 38 - 39 and 35 - 36 h prior to ovum pick-up, respectively \] with HCG in triggering ovulation in patients with expected poor response to ovarian stimulation
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT06754332
The Study of Human Chorionic Gonadotropin (HCG) Activating the Dormant Follicles .
Phase 1
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
About 60 people
Starts Apr 1, 2025 (estimated)
In plain words A Phase 1 study of hCG in female participants 20 to 39, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. It plans to enroll about 60 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 20 to 39. Conditions: Premature Ovarian Insufficiency.
Females under 40 years of age with amenorrhea or oligomenorrhea for at least four months, and elevated follicle-stimulating hormone (FSH) levels > 25 IU/l on two separate occasions (with a 4-week interval);
Ultrasound (B-mode) indicating no antral follicle development in both ovaries for at least 3 months prior to study participation;
Those who agree to participate in this study and voluntarily sign the informed consent form.
The exclusion criteria are on the listing.
What it tests, as registered
human chorionic gonadotropin
Registered summary
This project aims to activate dormant follicles in patients with premature ovarian insufficiency by injecting human chorionic gonadotropin (hCG) to explore the feasibility of a treatment plan that stimulates the growth of dormant follicles, not visible to the naked eye, to antral follicles visible under ultrasound, without visible follicle growth. The project also seeks to enable patients to conceive offspring carrying their own genetic material through in vitro fertilization (IVF) technology.